European Association for the Study of the Liver Congress
EASL 2025 7 - 10 May 2025

Semaglutide-treated participants in the phase 3 ESSENCE trial (part 1) have greater concordance of non-invasive test improvements compared with placebo

Authors :

Mary E. Rinella1; Manal F. Abdelmalek2; Elisabetta Bugianesi3; Anna M.G. Calí4; Laurent Castera5,6; Kristiane A. Engebretsen4; Jacob George7; Wah Kheong Chan8; Niels Krarup4; Michelle T. Long4; Philip Newsome9,10; Cláudia P. Oliveira11; Georgios Papatheodoridis12; Ahsan Shoeb4; Salvatore Petta13; Michael Roden14,15,16; Arun J. Sanyal17; Yusuf Yilmaz18; Vlad Ratziu19; on behalf of the ESSENCE Study Group
Affiliations
View Details Hide Details
{{ getPageNum(PDFPage) }}
Keywords
MASH
Congress poster
GLP-1 RA
Semaglutide
PHASE 3 (RCT)